10.5  0 (0%)		12-31 19:00
Open: 10.49 High: 10.5 Volume: 63,651		Pre. Close: 10.5 Low: 10.49 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	12.26	1-year :	14.32
Resists	First :	10.5	Second :	12.26
Pivot price	10.5
Supports	First :	10.49	Second :	10.48
MAs	MA(5) :	10.5	MA(20) :	10.5
	MA(100) :	10.5	MA(250) :	7.51
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	100	D(3) :	100
RSI	RSI(14): 88.8
52-week	High :	10.5	Low :	2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CMPI ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	10.51 - 10.56	10.56 - 10.6
Low:	10.37 - 10.43	10.43 - 10.48
Close:	10.41 - 10.5	10.5 - 10.58

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Thu, 12 May 2022
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update - GlobeNewswire

Tue, 19 Apr 2022
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in ... - GlobeNewswire

Fri, 08 Apr 2022
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association ... - GlobeNewswire

Tue, 29 Mar 2022
Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update - GlobeNewswire

Wed, 09 Feb 2022
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO - GlobeNewswire

Mon, 20 Dec 2021
Checkmate Pharmaceuticals Appoints Joy Yan, M.D., Ph.D. to Board - citybiz

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	22 (M)
Shares Float	7 (M)
Held by Insiders	4.6 (%)
Held by Institutions	77.5 (%)
Shares Short	79 (K)
Shares Short P.Month	42 (K)

EPS	-2.93
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.53
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-42.4 %
Return on Equity (ttm)	-75.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-50 (M)
Levered Free Cash Flow	-24 (M)

PE Ratio	-3.6
PEG Ratio	-0.1
Price to Book value	4.13
Price to Sales	0
Price to Cash Flow	-4.63

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.